Poster Abstracts • OFID 2017:4 (Suppl 1) • S365 Conclusion. Tis is the largest data evaluating microbiology of infected walled of necrosis. Organisms isolated are mostly colonizers of skin and gastrointestinal tract. Positive cultures were seen more in obese and elder patients. Clinical correlation is needed when deciding whether to treat these organisms or not. Disclosures. R. Kozarek, Boston Scientifc: Investigator, Research support  1193. Risk Factors for the Development of Bacteremia in Previously Healthy Children with Non-typhoidal Salmonella Gastroenteritis Bethany Burdick, Medical Student 1 ; Ankhi Dutta, MD, MPH 2 ; Lauren Hess, MD 1 and Charles Minard, PhD 1 ; 1 Baylor College of Medicine, Houston, Texas, 2 Pediatrics, Texas Children’s Hospital, Houston, Texas Session: 146. Enteric Infections and Diagnostics Friday, October 6, 2017: 12:30 PM Background. Non-typhoidal Salmonella (NTS) causes approximately 1.2 million illnesses per year in the United States. Tere are very few pediatric studies which has investigated the risk factors for NTS bacteremia in healthy children with NTS gastro- enteritis (NTS-AGE). Methods. Tis was a retrospective study of children admitted to Texas Children’s Hospital, Houston, TX, with NTS-AGE from 2007–2016. Exclusion criteria included: patients aged ≤3 m or > 18 years, immunodefciencies, hemoglobinopathies, extraintestinal manifestations or those in whom blood cultures were not obtained. Demographics, clinical and laboratory data were collected from electronic medical records. Patients with NTS bacteremia (NTS-B) were compared with patients who were non-bacteremic (NTS-NB). Results. Of 350 patients reviewed, 83 patients met inclusion criteria: 53 with NTS-B and 30 NTS-NB. Te median age of diagnosis was 1.58 years (range 3.5 months-18 years). Tirty-nine patients (47.0%) were female and 44 (53.0%) were male. Majority of patients were non-Hispanic White (n = 70; 84.3%). Te most com- mon serotype was Salmonella Group C (n = 41(49.4%). Tere was no diference in risk factors between NTS-B vs. NTS-NB in terms of age, duration of diarrhea prior to admission, travel or pet exposure, prior antibiotic exposure or white blood cell count at presentation. Duration of fever prior to admission was statistically signifcant with median duration for NTS-B being 6.11 days compared with NTS-NB at 1.97 days (P = 0.0000006). Tere was an increased trend for bacteremia in males and Salmonella Group C bacteremia (P = 0.07 and P = 0.08 respectively). Conclusion. To our knowledge this is frst pediatric study in the United States to evaluate risk factors for NTS bacteremia in healthy children with NTS-AGE. Duration of fever prior to admission was associated with increased risk of NTS-B along with increased trend with males and infection with Group C Salmonella. Tese risk factors should prompt clinicians to monitor patients with NTS-AGE closely and help in decid- ing whether antimicrobials are warranted or not. Disclosures. All authors: No reported disclosures.  1194. Clinically Important Resistance among Salmonella enterica Serotype Typhi Isolates—United States, 2003–2015 Felicita Medalla, MD, MS; Louise Francois Watkins, MD, MPH; Kevin Chatham- Stephens, MD, MPH; Jared Reynolds, MPH; Amelia Bicknese, BS and Cindy Friedman, MD; Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia Session: 146. Enteric Infections and Diagnostics Friday, October 6, 2017: 12:30 PM Background. Salmonella Typhi (Typhi) causes typhoid fever, accounting for an estimated 5,700 illnesses and 623 hospitalizations per year in the United States. Most infections are acquired during travel to regions outside the United States where typhoid fever is prevalent and antimicrobial resistance is a problem. Fluoroquinolones (e.g., cip- rofoxacin) are considered the treatment of choice for susceptible Typhi infections due to their superior ability to concentrate intracellularly and in bile, however, nonsuscep- tibility has been associated with treatment failure or delayed response. Azithromycin and cefriaxone are treatment options. We describe antimicrobial susceptibility among Typhi isolates in the United States and the implications for management. Methods. Te National Antimicrobial Resistance Monitoring System at CDC conducts susceptibility testing on all Typhi isolates submitted by public health labo- ratories. We used broth microdilution to determine minimum inhibitory concentra- tions (MICs) to agents representing 9 antimicrobial classes and categorized isolates according to criteria from the Clinical and Laboratory Standards Institute. We defned ciprofoxacin nonsusceptibility as MIC ≥0.12 μg/mL, ciprofoxacin resistance as MIC ≥1, azithromycin resistance as MIC ≥32, and cefriaxone resistance as MIC ≥4. Results. From 2003–2015, isolates were tested from 4,550 patients; 2,760 (61%) were ciprofoxacin nonsusceptible, 4% were ciprofoxacin resistant. One isolate was azithromycin resistant and none were cefriaxone resistant. Ciprofoxacin nonsuscep- tibility increased from 39% in 2003 to 66% in 2015; resistance increased from 0.3% to 8%. Median age of patients was 23 years (range 1–99 years), 53% were male, most were from the Northeast (33%) or the West (29%), and 74% had an isolate from blood. Conclusion. Two thirds of Typhi isolates exhibited ciprofoxacin nonsusceptibil- ity, which has increased over the last decade, and full resistance is increasing. Clinicians should be aware of high rates of fuoroquinolone nonsusceptibility when selecting empiric therapy and should tailor antimicrobial treatment to susceptibility results when feasible. Azithromycin and cefriaxone remain important treatment options. Disclosures. All authors: No reported disclosures.  1195. Impact of Fecal Microbiota Transplantation on Digestive Tract Colonization due to Carbapenem-resistant Enterobacteriacae and Vancomycin- resistant Enterococci Benjamin Davido, MD, MS 1 ; Rui Batista, PharmD 2 ; Hugues Michelon, PharmD, MS 3 ; Lelia Escaut, M.D 4 ; Hafedh Fessi, MD 5 ; Olivia Senard, MD 6 ; Morgan Matt, MD 7 ; Laurene Deconinck, MD 7 ; Pierre De Truchis, MD, PhD 7 ; Jérôme Salomon, MD, PhD 8 and Aurelien Dinh, MD 9 ; 1 Infectious Diseases, Hopital Raymond Poincaré, AP-HP, Garches, France, 2 Pharmacy Unit, Hopital Cochin, AP-HP, Paris, France, 3 Pharmacy Unit, Hopital Raymond Poincaré, AP-HP, Garches, France, 4 Hopital Kremlin Bicètre, AP-HP, Kremlin Bicètre, France, 5 Nephrology, Hopital Tenon, AP-HP, Paris, France, 6 Infectious Diseases, Hôpital Raymond Poincaré-UVSQ, Garches, France, 7 Hopital Raymond Poincaré, AP-HP, Garches, France, 8 Infectious Diseases, Hopital Raymond- Poincaré, AP-HP, Garches, France, 9 Garches University Hosp., Garches, France Session: 146. Enteric Infections and Diagnostics Friday, October 6, 2017: 12:30 PM Background. Fecal Microbiota Transplantation (FMT) has proved to be an ef- cient therapy for recurrent C. difcile infection. Its indication is currently discussed for the decolonization of Multidrug-resistant organisms (MDRO) on the basis of mice experiments. Two recent publications suggest that it could be an efcient strat- egy for patients colonized with digestive MDRO colonization but few data are avail- able for Carbapenem-Resistant Enterobacteria (CRE) and Vancomycin-Resistant Enterococcus (VRE) colonization. Methods. We performed a FMT among patients colonized by CRE or VRE doc- umented by at least 3 nonconsecutive positive swabs (including one in the week prior to the FMT). Procedure: 2 days prior to the FMT, patients received a proton pump inhibitor and a naso-duodenal tube was inserted to perform a bowel lavage with X-prep. FMT was performed with frozen feces from 4 donors previously screened for potential diseases using 5 syringes of 50 cc of feces diluted with saline. Patients were discharged afer 24h and benefted of outpatient control swabs (PCR + culture) on day 7, 14, 21, 28 and each month during 3 months in order to assess the decolonization. Te study is registered at ClinicalTrials.gov (NCT03029078). Results. Seventeen individuals were included. Mean age was 69 ± 12.7 (SD) years. Eight patients were positive for CRE (KPC, OXA48 or NDM-1) and 9 for VRE. All sufered from severe underlying condition (hemodialysis, dementia, cirrhosis) or chronic wounds. Median functional autonomy scale was evaluated using the French Iso-Resources Groups (GIR)=4/6 IQR[3–6] supporting they were dependent persons. At 1-month follow-up, 3/8 patients were free from CRE and 5/9 from VRE. At 3-month follow-up, 3/8 patients were still free from CRE whereas 7/8 were free from VRE, considering one death from cirrhosis. Moreover, one of them received antibiotics during a week for a hospital-acquired infection a long time afer FMT. No adverse events were reported. Conclusion. FMT seems to be an attractive option to eradicate colonization of MDRO, especially for VRE. Limited data are available in the literature to determine response factors. Meanwhile its efcacy is moderate; it provides an alternative solution to quarantine for fragile and frequently hospitalized patients. More data and a con- trolled trial are required. Disclosures. All authors: No reported disclosures.  1196. The Global Burden of Shigella and Enterotoxigenic E. coli: Results from the Global Burden of Disease Study 2016 Ibrahim Khalil, M.D, MPH; Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington Session: 146. Enteric Infections and Diagnostics Friday, October 6, 2017: 12:30 PM Background. Diarrhea is the seventh leading cause of death globally, responsible for more than 1,600,000 deaths in 2016 and nearly 90% of these deaths occurred in sub-Saharan Africa and South Asia. Te Global Burden of Disease Study (GBD) is an annual efort to produce and refne estimates of diarrheal disease burden attributable to Shigella spp., enterotoxigenic Escherichia coli (ETEC), and other enteric pathogens. Methods. We used a counter-factual approach to estimate deaths, incidence, years of life lost (YLLs), years living with disability (YLDs), and total disability adjusted life years (DALYs) attributable to diarrhea and its etiologies, including Shigella and ETEC. To estimate the burden of diarrhea etiologies, we conducted a systematic review of the proportion of diarrheal cases positive for each pathogen and modeled these data using a Bayesian meta-regression tool called DisMod-MR. Tis tool generates esti- mates of the pathogen distribution for national and some subnational geographies, all age groups, and for both sexes from 1990 to 2016. We used these estimates, in conjunc- tion with odds ratios for diarrhea given pathogen detection from the Global Enteric Multicenter Study, to calculate the population attributable fraction for each pathogen. Results. In 2016, Shigella was responsible for 75,000 deaths among children under-5 and 270,000 deaths among all ages and ETEC was responsible for 22,000 deaths among children under-5 and 60,000 deaths among all ages. Shigella and ETEC ranked second and fourth with regard to pathogen contributions to global diarrheal deaths. Conclusion. Te global burden of disease attributable to Shigella and ETEC is substantial. GBD 2016 estimates on the age- and location-specifc impact of Shigella and ETEC enable evidence-based decision making regarding interventions to reduce the burden of these pathogens. Our fndings call for accelerated eforts for the develop- ment of vaccines against ETEC and Shigella. Disclosures. All authors: No reported disclosures.